Hi Eddie,
Totally understand the connection between COVID-19 & DMX-700, a few of us were wondering about that before the ANN came out & the pulmonary connection there, but that is still in pre-clinical, so it kind of didn’t make sense in a PH4 trial. DMX-200 does on the new RAAS arm, and reflecting on comments from Dimerix, that we are in a unique position here, I’m just wondering when this protocol is published on REMAP-CAP website, will DMX-200 + ARB possibly be the only drug at this point in time?
It’s still an IND so that in itself to convince the International REMAP-CAP medical advisory board to include DMX-200 on the trial is pretty special, there would have to be very compelling evidence. I did bring my laptop home from work this weekend so will do some searches on CIAP & share here.
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-595
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
-0.060(9.84%) |
Mkt cap ! $302.3M | |||
| Open | High | Low | Value | Volume |
| 60.5¢ | 61.0¢ | 55.0¢ | $2.309M | 4.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 137019 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.5¢ | 22500 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |